A prospective observational study to validate treatment strategies for patients with gastric cancer or esophagogastric junctional cancer who received chemotherapy as initial treatment

A prospective observational study to validate treatment strategies for patients with gastric cancer or esophagogastric junctional cancer who received chemotherapy as initial treatment - A prospective observational study to validate treatment strategies for patients with gastric cancer or esophagogastric junctional cancer who received chemotherapy as initial treatment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051320

Enrollment

100

Registered

2023-09-09

Start date

2020-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer or esophagogastric junction cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients aged 20 years or older at the time of informed consent. 2)Histologically diagnosed with gastric cancer or esophagogastric junction cancer 3) Patients with an ECOG Performance Status of 0-1. 4)Patients who have preserved heart, lung, liver, kidney and bone marrow functions and who meet all of the following laboratory test values. a. Renal function: BUN less than 1.5 times the facility's upper limit of normal values Serum creatinine level less than 1.5 times the facility's upper limit of normal values b. Liver function: AST (GOT) less than 1.5 times the facility's upper limit of normal values ALT (GPT) less than 1.5 times the facility's upper limit of normal values Serum total bilirubin level less than 1.5 times the facility's upper limit of normal values c. Blood: Neutrophils 1,500/mm3 or more Platelet count 100,000/mm3 or more Hb 8.0 g/dL or more d. Cardiac function Electrocardiogram: no serious abnormalities e. Lung function Pulmonary function: arterial blood oxygen saturation (Sp02) more than 94% (without oxygen administration) 5) Patients with no other active double cancers (including hematologic malignancies). 6)Patients who have been informed of their disease name and condition, who have received an explanation of this study, and who are able to obtain written consent after understanding the content.

Exclusion criteria

Exclusion criteria: 1) Patients with uncontrolled infections (including active tuberculosis). 2) Serious complications (malignant hypertension, severe congestive heart failure, severe or unstable angina pectoris, myocardial infarction within 3 months before consent, end-stage liver cirrhosis, severe renal failure or chronic renal failure requiring hemodialysis , uncontrolled diabetes, severe pulmonary fibrosis, active interstitial pneumonia, etc.). 3) Patients after allogeneic bone marrow transplantation. 4)Patients with severe mental disorders. 5) Pregnant women, breastfeeding women, or patients who may be pregnant. 6) Patients who are otherwise judged to be ineligible by the principal investigator or co-investigator.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactKei Yamamoto

Osaka International Cancer Institute Gastroenterological Surgery

kei.yamamoto@oici.jp+81-6-6945-1181

Outcome results